Interleukin-6 and total antioxidant capacity levels following N-acetylcysteine and a combination nutraceutical intervention in a randomised controlled trial for bipolar disorder.

Chiara C BortolasciC VoigtA TurnerM MohebbiL GrayS DoddK WalderM BerkS M CottonGin S MalhiC H NgN DowlingJ SarrisO M Dean

Published in: Acta neuropsychiatrica (2020)

Participants with lower IL-6 levels at baseline had a better response to the adjunctive treatment with the mitochondrial-enhancing agents in terms of improvements in MADRS and CGI-I outcomes.

Keyphrases

bipolar disorder
randomized controlled trial
major depressive disorder
oxidative stress
type diabetes
metabolic syndrome
insulin resistance
replacement therapy